These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27669229)

  • 1. The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models.
    Ribback S; Sailer V; Böhning E; Günther J; Merz J; Steinmüller F; Utpatel K; Cigliano A; Peters K; Pilo MG; Evert M; Calvisi DF; Dombrowski F
    Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis.
    Schiffer E; Housset C; Cacheux W; Wendum D; Desbois-Mouthon C; Rey C; Clergue F; Poupon R; Barbu V; Rosmorduc O
    Hepatology; 2005 Feb; 41(2):307-14. PubMed ID: 15660382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
    Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
    Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.
    Höpfner M; Sutter AP; Huether A; Schuppan D; Zeitz M; Scherübl H
    J Hepatol; 2004 Dec; 41(6):1008-16. PubMed ID: 15582135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gefitinib and the modulation of the signaling pathways downstream of epidermal growth factor receptor in human liver cancer cells.
    Okano J; Matsumoto K; Nagahara T; Murawaki Y
    J Gastroenterol; 2006 Feb; 41(2):166-76. PubMed ID: 16568376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and metabolic changes in human liver clear cell foci resemble the alterations occurring in rat hepatocarcinogenesis.
    Ribback S; Calvisi DF; Cigliano A; Sailer V; Peters M; Rausch J; Heidecke CD; Birth M; Dombrowski F
    J Hepatol; 2013 Jun; 58(6):1147-56. PubMed ID: 23348238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
    Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
    Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib.
    Ueda S; Basaki Y; Yoshie M; Ogawa K; Sakisaka S; Kuwano M; Ono M
    Cancer Res; 2006 May; 66(10):5346-53. PubMed ID: 16707461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib.
    Desbois-Mouthon C; Cacheux W; Blivet-Van Eggelpoël MJ; Barbu V; Fartoux L; Poupon R; Housset C; Rosmorduc O
    Int J Cancer; 2006 Dec; 119(11):2557-66. PubMed ID: 16988945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of fatty acid synthase in chemically and hormonally induced hepatocarcinogenesis of the rat.
    Evert M; Schneider-Stock R; Dombrowski F
    Lab Invest; 2005 Jan; 85(1):99-108. PubMed ID: 15543204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular neoplasms after intrahepatic transplantation of ovarian fragments into ovariectomized rats.
    Dombrowski F; Flaschka C; Klotz L; von Netzer B; Schulz C; Lehnert H; Evert M
    Hepatology; 2006 Apr; 43(4):857-67. PubMed ID: 16557532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cocarcinogenic effects of islet hormones and N-nitrosomorpholine in hepatocarcinogenesis after intrahepatic transplantation of pancreatic islets in streptozotocin-diabetic rats.
    Dombrowski F; Jost CM; Manekeller S; Evert M
    Cancer Res; 2005 Aug; 65(15):7013-22. PubMed ID: 16061688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement and phenotypic modulation of N-nitrosomorpholine-induced hepatocarcinogenesis by dehydroepiandrosterone.
    Metzger C; Bannasch P; Mayer D
    Cancer Lett; 1997 Dec; 121(2):125-31. PubMed ID: 9570349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose and time dependence of the cellular phenotype in rat hepatic preneoplasia and neoplasia induced in stop experiments by oral exposure to N-nitrosomorpholine.
    Weber E; Bannasch P
    Carcinogenesis; 1994 Jun; 15(6):1227-34. PubMed ID: 8020160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.
    Blivet-Van Eggelpoël MJ; Chettouh H; Fartoux L; Aoudjehane L; Barbu V; Rey C; Priam S; Housset C; Rosmorduc O; Desbois-Mouthon C
    J Hepatol; 2012 Jul; 57(1):108-15. PubMed ID: 22414764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer.
    Yan Y; Lu Y; Wang M; Vikis H; Yao R; Wang Y; Lubet RA; You M
    Mol Cancer Res; 2006 Dec; 4(12):971-81. PubMed ID: 17189387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
    Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
    Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
    Pino MS; Shrader M; Baker CH; Cognetti F; Xiong HQ; Abbruzzese JL; McConkey DJ
    Cancer Res; 2006 Apr; 66(7):3802-12. PubMed ID: 16585207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.